WATERTOWN, Mass., Dec. 28, 2015 (GLOBE NEWSWIRE) -- pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader...
Statistical Significance in Improvement in Visual Acuity and Reduction in Systemic Therapy ...
WATERTOWN, Mass., Nov. 05, 2015 (GLOBE NEWSWIRE) -- pSivida Corp. (NASDAQ:PSDV), (ASX:PVA), a leader...
WATERTOWN, Mass., Oct. 30, 2015 (GLOBE NEWSWIRE) -- pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in the development of sustained release...
Top-Line Data from First Trial Expected December 2015 pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in the development of sustained...
pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in the development of sustained release drug delivery products for treating eye diseases...
pSivida Corp. (NASDAQ: PSDV, ASX: PVA), a leader in the development of sustained release, drug delivery products for treating eye diseases...
pSivida Corp. (NASDAQ:PSDV)(ASX:PVA), a leader in the development of sustained release drug delivery products for treating eye diseases...
Statistically Significant Reduction in Recurrence of Disease and Statistically Significant Improvement in Visual Acuity pSivida Corp...
Dr. Glenn J. Jaffe to Present at 33rd Annual Scientific Meeting of American Society of Retina Specialists pSivida Corp. (NASDAQ:PSDV...
pSivida Corp. (NASDAQ:PSDV; ASX:PVA), a leader in the development of sustained release drug delivery products for treating eye diseases...
pSivida Corp. (NASDAQ:PSDV); (ASX:PVA), a leader in the development of sustained release drug delivery products for treating eye diseases...
pSivida Corp. (NASDAQ:PSDV; ASX:PVA), a leader in developing sustained release, drug delivery products for treating eye diseases, today...
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.